Wednesday, November 18, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Caterpillar Inc. (CAT) and Union Pacific Corp. (UNP), as well as two micro-cap stocks Daily Journal Corp. (DJCO) and Community Bancorp (CMTV). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Fight into the Green Ahead of Anthropic IPO
Today's Featured Research Reports
Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+55.3% vs. +30.5%). The company’s Q3 earnings and sales beat estimates. Its blockbuster drug, Keytruda, and newer products such as Winrevair and Welireg are driving sales. Animal Health is also contributing to growth. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.
Merk’s new products, pipeline progress, and business development and acquisitions have increased confidence that it may be able to maintain growth even after Keytruda loses exclusivity.
However, it faces several challenges, including persistent challenges for Gardasil, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs. Merck expects moderate revenue growth in 2027, with gains from new launches and Animal Health partly offset by generic erosion of drugs like Bridion and Januvia.
(You can read the full research report on Merck here >>>)
Shares of Caterpillar have outperformed the Zacks Manufacturing - Construction and Mining industry over the past year (+4% vs. -2.9%). The company benefits from demand across construction, mining and power markets, with a record backlog providing revenue visibility. Power & Energy gains from data-center electricity needs and gas compression, while capacity additions support longer-term growth.
Construction activity and rental investment remain favorable, and mining replacement demand supports equipment orders. Technology adoption, services growth and cash generation reinforce the investment case.
However, tariffs, freight inflation and spending on new capacity can restrain margins despite sales. Uneven regional demand, mining delivery timing and dealer inventory adjustments add execution risk. Although management maintained its annual sales outlook, the balance of growth opportunities, cost exposure and valuation warrants a Neutral recommendation.
(You can read the full research report on Caterpillar here >>>)
Union Pacific’s shares have outperformed the Zacks Transportation - Rail industry over the past year (+37.1% vs. +36.7%). The company’s extensive rail network, intermodal franchise and reliable service support growth despite uneven freight demand. Domestic intermodal gains and improving international traffic broaden volume opportunities.
Pricing discipline and network productivity underpin earnings resilience, while cash generation and lower leverage support reinvestment and dividends. The proposed Norfolk Southern combination offers network benefits but carries regulatory, financing and integration uncertainty.
Coal weakness, softer automotive demand and shifting trade flows limit visibility. Elevated fuel costs and labor inflation could constrain reported margins despite efficiency gains. With repurchases largely suspended ahead of the transaction, the balance of operating strength and execution risks supports a Neutral recommendation.
(You can read the full research report on Union Pacific here >>>)
Shares of Daily Journal have outperformed the Zacks Publishing - Newspapers industry over the past year (+53.2% vs. +9.6%). This microcap company with a market capitalization of $824.84 million is benefiting from strong momentum at Journal Technologies, where nine-month revenues rose 21% to $55.6 million and pretax income more than doubled to $9.8 million as revenue growth outpaced expenses. The software unit now generates about 80% of consolidated revenues, while growth in licensing, maintenance, e-filing and consulting underscores broad-based momentum.
Higher deferred revenue and $16.3 million of revenue recognized from beginning-period deferred balances also provide greater visibility. Strong liquidity, $12.9 million of operating cash flow and continued debt reduction enhance financial flexibility and support further software investment.
However, the concentrated $406 million securities portfolio creates earnings volatility, while elevated costs and weakness in the Traditional Business remain risks. The stock trades at attractive price/book discount versus peers.
(You can read the full research report on Daily Journal here >>>)
Community Bancorp’s shares have outperformed the Zacks Banks - Northeast industry over the past year (+113.3% vs. +30.5%). This microcap company with a market capitalization of $272.54 million sees its investment case rest on expanding lending income, lower wholesale funding costs and improved operating efficiency.
Residential loan purchases broaden earning assets and geographic exposure, while limited realized losses and retained earnings provide capacity to support growth. Greater participation in trust and wealth management adds a source of income beyond banking spreads, although market weakness has reduced its contribution. Nasdaq trading and index inclusion broaden investor visibility, complementing book value growth and dividends.
These drivers support the earnings outlook despite rising nonaccrual loans, commercial real estate exposure and recurring expense pressure. Seasonal deposit movements and sensitivity to interest rates require disciplined funding and credit management as lending expands.
(You can read the full research report on Community Bancorp here >>>)
Other noteworthy reports we are featuring today include IDEXX Laboratories, Inc. (IDXX), GE HealthCare Technologies Inc. (GEHC) and EMCOR Group, Inc. (EME).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>